Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Saori Watanabe Miyano
Observed names:
S. Watanabe Miyano,
SAORI WATANABE MIYANO,
Saori W. Miyano,
Saori Watanabe-Miyano
Institution:
Eisai (Japan)
Observed institutions:
University of Tsukuba,
Eisai (Japan)
OpenAlex ID:
A5044623118
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades
2019
·
Taisuke Hoshi
, Saori Watanabe Miyano
, et al.
·
Biochemical and Biophysical Research Communications
·
84
PDF
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
2020
·
Kenji Ichikawa
, Saori Watanabe Miyano
, et al.
·
Scientific Reports
·
66
PDF
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2016
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
·
Molecular Cancer Therapeutics
·
44
PDF
Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion
2024
·
SATOSHI KAWANO
, MEGUMI IKEMORI KAWADA
, et al.
·
Anticancer Research
·
10
Abstract 4089: Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model
2019
·
Taro Semba
, Kimiyo Tabata
, et al.
·
Cancer Research
·
6
Abstract 1374: Lenvatinib, tri-specific targeted therapy to VEGFR/FGFR/RET, suppresses angiogenesis through the inhibition of both VEGFR and FGFR signaling pathways
2015
·
Kenji Ichikawa
, Saori Watanabe Miyano
, et al.
·
Cancer Research
·
6
Synthesis and structure–activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors
2014
·
Satoshi Nagao
, Yoshinobu Yamane
, et al.
·
Bioorganic & Medicinal Chemistry
·
6
Abstract 1414: Effect of E7090, an FGFR1-3 selective inhibitor, on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2(-) breast cancer preclinical models
2021
·
Satoshi Kawano
, Sayo Fukushima
, et al.
·
Cancer Research
·
4
Abstract 2095: E7090, a novel and selective FGFR inhibitor, for the treatment of cholangiocarcinoma cells harboring FGFR2-fusion genes
2017
·
Saori W. Miyano
, Yasuhito Arai
, et al.
·
Cancer Research
·
3
Abstract 770: E7090: A potent and selective FGFR inhibitor with activity in multiple FGFR-driven cancer models with distinct mechanisms of activation
2015
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
·
Cancer Research
·
3
Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models
2025
·
Satoshi Kawano
, Sayo Fukushima
, et al.
·
Cancers
·
1
65 (PB053): Effect of tasurgratinib as an orally available FGFR1-3 inhibitor on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2 (-) breast cancer preclinical models
2024
·
S. Kawano
, S. Fukushima
, et al.
·
European Journal of Cancer
·
1
Abstract 1830: E7386, a selective inhibitor of the interaction between β-catenin and CREB-binding protein (CBP), in combination with lenvatinib (LEN), exerts antitumor activity in preclinical tumor models with prior immune checkpoint inhibitor (ICI)-based combination treatment
2023
·
Satoshi Kawano
, Yusuke Adachi
, et al.
·
Cancer Research
·
1
Abstract 6637: Inhibition of FGFR signaling by lenvatinib activates tumor interferon gamma signaling pathway and potentiates antitumor activity of anti-PD-1 antibody
2020
·
Yusuke Adachi
, Hiroshi Kamiyama
, et al.
·
Cancer Research
·
1
Supplementary Document from Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
2025
·
Yusuke Adachi
, Hiroshi Kamiyama
, et al.
Supplementary Figures from Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
2025
·
Yusuke Adachi
, Hiroshi Kamiyama
, et al.
PDF
Supplementary Figures from Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
2023
·
Yusuke Adachi
, Hiroshi Kamiyama
, et al.
PDF
Data from Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
2023
·
Yusuke Adachi
, Hiroshi Kamiyama
, et al.
Supplementary Document from Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
2023
·
Yusuke Adachi
, Hiroshi Kamiyama
, et al.
Data from Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
2023
·
Yusuke Adachi
, Hiroshi Kamiyama
, et al.
Data from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2023
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
Supplementary Table S1 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2023
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
Supplementary Figure S2 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2023
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
Supplementary Table S2 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2023
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
Supplementary Figure S4 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2023
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
Show more works
View as search
Works count:
41
Citation count:
236
H-index:
6
I10-index:
4
Year
Topic
Type